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Abstract
Background: Severe leptospirosis features bleeding and multi-organ failure, leading to shock and death. Currently it is
assumed that both exaggerated inflammation and immune suppression contribute to mortality in sepsis. Indeed, several
proinflammatory cytokines are reported to be induced during leptospirosis. Toll-like receptors, which play an important role
in the initiation of an innate immune response, are inhibited by negative regulators including the membrane-bound ST2
(mST2) receptor. Soluble ST2 (sST2) has been implicated to inhibit signaling through mST2. The aim of this study was to
determine the extent of sST2 and (pro-) inflammatory cytokine release in patients with severe leptospirosis.
Methodology and Principal Findings: In an observational study, 68 consecutive cases of severe leptospirosis were included.
Soluble ST2 and cytokines (TNF-a, IL-1b, IL-6, IL-8, and IL-10) were repeatedly measured. To determine whether blood cells
are a source of sST2 during infection, we undertook an in vitro experiment: human whole blood and peripheral blood
mononuclear cells (PBMC) were stimulated with viable pathogenic Leptospira. All patients showed elevated sST2, IL-6, IL-8,
and IL-10 levels on admission. Admission sST2 levels correlated with IL-6, IL-8, and IL-10. Thirty-four patients (50%) showed
clinical bleeding. Soluble ST2 levels were significantly associated with bleeding overall (OR 2.0; 95%CI: 1.2–3.6) and severe
bleeding (OR 5.1; 95%CI: 1.1–23.8). This association was unique, since none of the cytokines showed this correlation.
Moreover, sST2 was associated with mortality (OR 2.4; 95%CI: 1.0–5.8). When either whole blood or isolated PBMCs were
stimulated with Leptospira in vitro, no sST2 production could be detected.
Conclusions: Patients with severe leptospirosis demonstrated elevated plasma sST2 levels. Soluble ST2 levels were
associated with bleeding and mortality. In vitro experiments showed that (white) blood cells are probably not the source. In
this regard, sST2 could be an indicative marker for tissue damage in patients suffering from severe leptospirosis.
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Introduction
Leptospirosis is a worldwide occurring zoonosis [1], reported to
be fatal in up to 50% of cases [2]. The disease is caused by
spirochetes that are spread by the urine of infected animals, for
example rats, mice and cattle amongst others. Survival of Leptospira
is enhanced in a warm and humid environment, where
environmental circumstances are most favourable. Hence preva-
lence is higher in (sub) tropical countries. Severe leptospirosis is
featured by bleeding complications and multi-organ failure, which
can eventually lead to shock and even death. Necropsy reports
confirm widespread haemorrhaging throughout the body, involv-
ing most vital organs and tissues [3]. This haemorrhaging could
possibly be the result of capillary wall damage.
Several proinflammatory cytokines, such as TNF-a and IL-
12p40 are reported to be induced during infection with Leptospira
[4,5]. As well, elevated plasma concentrations of TNF-a have been
associated with lethal outcome amongst leptospirosis patients [6],
In a hamster model, late expression of the anti-inflammatory
cytokines IL-4, TGF-b and IL-10 have been shown [7].
Currently it is assumed that both exaggerated inflammation and
immune suppression contribute to an adverse outcome in sepsis
[8]. ST2, also designated T1, Fit-1 and DER4, is thought to play a
significant role in tuning the host inflammatory response. ST2 is a
receptor that is present in two main forms, in the soluble secreted
form (sST2) [9] and in a membrane-anchored form (ST2L) [10].
Both are encoded from the ST2 gene regulated by different
promoters [11] and are members of the IL-1 receptor family. ST2
gene expression was identified originally in fibroblasts [9,12].
Expression has also been detected in several other cells, including
Th2 cells, mast cells and macrophages [13–16].
ST2L has been reported to attenuate downstream IL-1RI and
TLR4 signalling by sequestering MyD88 and MAL (MyD88
adaptor-like) [17]. In contrast, previous work has demonstrated
that interleukin (IL)-33 is able to activate NF-kB and MAP kinases
by signaling through ST2L [18]. IL-33/ST2L signalling in mast
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cytokines, potentially balancing ongoing inflammatory Th1
responses [18].
The functional role of soluble ST2 has not yet been fully
elucidated. Elevated concentrations of sST2 have been found in
patients with inflammatory disorders associated with abnormal
Th2 mediated responses, in for example, autoimmune diseases
[19], asthma [20], idiopathic pulmonary fibrosis [21] and in
patients with sepsis [22]. Moreover sST2 have also been proposed
as a biomarker for heart failure [23] and elevated levels have been
seen to be predictive for clinical outcome in acute myocardial
infarction [24].
By using a soluble ST2-Immunoglobulin fusion protein, Sweet
et al. demonstrated that this molecule was able to bind
macrophages through a putative ST2 receptor, the expression of
which was enhanced by LPS stimulation [25]. Furthermore this
molecule was shown to suppress LPS-induced proinflammatory
response (TNF-a, IL-6 and IL-12) in vitro and reduced inflamma-
tion and mortality in LPS challenged mice [25]. Administration of
soluble ST2-Immunoglobulin fusion protein markedly reduced
proinflammatory cytokine production and lethality in intestinal
ischemia/reperfusion injury in mice [26]. The anti-inflammatory
effect exerted by sST2-Fc was dependent on the elevated
production of IL-10. Similar results were seen in hepatic
ischemia/reperfusion injury [27]. sST2-Fc fusion protein admin-
istration also shown to have beneficial effects in a murine model of
collagen-induced arthritis [28]. Asthmatic mice administered with
sST2-Fc fusion protein or a soluble ST2 expressing vector showed
attenuated production of the Th2 cytokines IL-4 and IL-5 [29,30],
whereas ST2L signaling resulted in the opposite. sST2 has
therefore been proposed to act as a decoy receptor for IL-33
[31,32].
To the best of our knowledge, in previous literature plasma
levels of sST2 have not been documented in leptospirosis patients.
Hence, in the present study we evaluate sST2, cytokine kinetics
and their association with clinical events in a series of severe
leptospirosis patients.
Methods
Ethics statement
The study protocol was approved by the medical ethic
committees of both the Dr. Kariadi hospital- University of
Diponegoro, Semarang, Indonesia and the Slotervaart Hospital
in The Netherlands. Written informed consent was obtained from
all included subjects.
Patients and design
Consecutive cases of severe leptospirosis were included from
February 2005 to September 2006 at the Dr. Kariadi hospital-
University of Diponegoro, Semarang, Indonesia. Severe leptospi-
rosis was defined as a hospitalized patient with high clinical
suspicion of severe leptospirosis a positive LeptoTek Dri-Dot assay
(Biome ´rieux), presenting with at least one of the following
symptoms or signs jaundice, renal failure, thrombocytopenia
and/or haemorrhaging..Cases were confirmed by further labora-
tory testing. Blood samples were taken on hospital admission and
during follow up. Plasma was worked up immediately and aliquots
were stored at 270uC for further analyses. Twenty control (non-
leptospirosis patients) samples were collected among healthy
volunteers at the department of internal medicine of the Dr.
Kariadi hospital- University of Diponegoro, Semarang, Indonesia.
Measurements and assays
Soluble ST2 was measured by the commercially available
ELISA (R&D systems, Minneapolis, MN). Tumor necrosis factor
(TNF)-a, IL-1ß, IL-6, IL-8, IL-10, and IL-12p70 were determined
using a cytometric beads array multiplex assay (BD Biosciences,
San Jose, CA). The detection limits were as follows, TNF-a, IL-10
(2.5 pg/ml); IL-1ß, IL-6, IL-8 (5 pg/ml); IL-12p70 (10 pg/ml);
sST2 (15 pg/ml).
Leptospirosis was confirmed by either a positive culture or
microscopic agglutination test (MAT). Tests were considered
positive for the MAT with a titre of $1:320 on a single sample,
seroconversion or a fourfold or higher increase of the titre in
paired samples or a titre $1:80 in a single sample from early
deceased patients.
In vitro experiments
To determine whether blood cells are an important source of
sST2 during infection, we undertook an in vitro experiment. We
used either human whole blood or peripheral blood mononuclear
cells (PBMCs), which were then stimulated with Leptospira interrogans
serovar Bataviae strain M, as this serovar is commonly found in
the region. This was a fresh, low passage isolate obtained from the
Leptospirosis Reference Center in Amsterdam, The Netherlands.
For the in vitro experiments, bacteria were washed 3 times with
RPMI 1640 (Gibco) and counted using a Helber Counting
Chamber (Hawksley, Lancing, Sussex, UK) under darkfield
microscopy and then resuspended at concentrations of 2.5610
7
till 2.5610
5 bacteria per ml. Shortly before starting the
experiment, heparinized blood was sterilely drawn from multiple
healthy donors and diluted 1:1 in RPMI. PBMC were obtained
using Lymphoprep
TM (Axis-Shield) according to the manufactur-
er’s guidelines. Whole blood (50 ml per well) or PBMC were
divided over each well of a 96-well plate before Leptospira
concentrates were added. The concentration PBMC was equiv-
alent to 50 ml whole blood per well (approximately 0.5610
9
monocytes). Plates were incubated for six hours at 37uC, 5% CO2.
Following incubation the plates were centrifuged and supernatant
was collected and stored at 270uC for further testing. All
Author Summary
Leptospirosis is a bacterial disease that is mainly spread by
rodents and other small mammals. Transmission frequent-
ly occurs in (sub-) tropical countries, where environmental
circumstances are most favourable. Severe leptospirosis
can cause bleeding and vital organ dysfunction. An
exaggerated immune response is thought to play an
important role in the pathophysiology of leptospirosis.
Soluble ST2 (sST2) is thought to inhibit negative regulatory
pathways of this response. Soluble ST2 is produced by cells
that surround, for example, blood vessels, and several of
these blood cells play an important part in the host
immune response. In an observational study, we measured
the extent of sST2 release in patients suffering from severe
leptospirosis. We found that patients that died from
leptospirosis displayed higher levels of sST2. Moreover,
from this study we have seen that sST2 levels were
associated with bleeding, whereas other markers of
infection were not. In an experiment, we showed that
(white) blood cells did not seem to be the source of sST2
production. Damage to blood vessels is likely to cause
bleeding in leptospirosis patients, exposing sST2 produc-
ing cells like fibroblasts to the blood stream. Hence, we
believe that sST2 may be used as a marker for tissue
damage in patients suffering from severe leptospirosis.
Soluble ST2 in Severe Leptospirosis
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controls RPMI without bacteria was used.
Statistical analysis
Continuous variables were presented as medians with corre-
sponding interquartile ranges (IQR) and were statistically
evaluated using the non-parametric Mann-Whitney U test.
Correlation between soluble ST2, clinical characteristics and
cytokine levels in patients were determined using the Spearman
correlation coefficient (rho). Associations were calculated using a
binary logistic regression analysis and were expressed as odds
ratios (OR) and corresponding 95% confidence intervals (CI). An
OR .1 indicates that the risk of a clinical event is higher with the
increase of biomarker plasma levels and an OR of ,1 indicates
that the risk of a clinical event is lower with the increase of plasma
levels. Associations were further analyzed using the receiver-
operating-characteristic (ROC) approach by calculating the area
under the ROC curve (AUC). The AUC reflects the probability
that a patient with higher plasma levels has a higher chance of the
event than a patient with lower plasma levels. Log transformation
of the original variables was used to improve the goodness of fit of
the model. A p-value of ,0.05 was considered to indicate
statistical significance. All analyses were done using SPSS (version
15.0, Chicago, Illinois).
Results
Characteristics of included patients
In total 68 leptospirosis patients were included, of which 49
(72%) were male. The median age (IQR) was 45 (34–55) years old.
In total 16 patients (24%) did not survive, with a median (IQR)
time to death of 3 days post hospital admission. On average
patient’s symptoms had started at a median of 7 days pre hospital
admission. Clinical manifestations/symptoms included jaundice
(75%), thrombocytopenia (platelets ,100610
9: 65%), oliguria
(19%) and anuria (4%). Median leucocyte, platelet, creatinine and
bilirubin levels were: 15610
9/L, 69610
9/L, 412 mmol/L and
113 mmol/L respectively. All patients had MAT serologically
confirmed leptospirosis, with the most frequently identified
serogroups being Bataviae (19), Icterohaemorrhagiae (18) and
Ballum (2).
All patients showed elevated sST2, IL-6, IL-8 and IL-10 levels
on admission, presented in Table 1. TNF-a, IL-1b and IL-12p70
levels taken at hospital admission were either very low or
undetectable and were not significantly different from the healthy
controls (data not shown). Patients that died from leptospirosis
(n=16) had significantly further elevated plasma levels on
admission compared to the survivors, sST2 (p=.006), IL-6
(p=.003) and IL-8 (p=.003). However, IL-10 (p=.64) was not
found to be significantly elevated. Figure 1 shows the dynamics of
sST2, IL-6, IL-8 and IL-10. Circulating sST2 levels in the
survivors showed a peak at day 0 after which levels gradually
decreased and normalized on day 7. However, patients who died
during their hospital stay displayed continuously high plasma
levels of sST2 until death occurred. Table 2 shows that admission
sST2 levels were significantly correlated with levels of IL-6 (rho
0.45; p=.001), IL-8 (rho 0.72; p,.0001), IL-10 (rho 0.56;
p,.0001) and CRP (rho 0.50; p,.0001) also taken at admission.
Admission sST2 levels resulted in moderate correlations with
respiratory rate (rho 20.25; p=.04), platelets (rho 20.25; p=.04)
creatinin (rho 0.33; p=.007), AST (rho 0.46; p=.001) levels and
(severe) haemorrhaging (haemorrhaging: rho 0.34; p=.005, severe
haemorrhaging: rho 0.32; p=.008).
Bleeding is associated with increased sST2 plasma levels
Since bleeding is an important feature of severe leptospirosis we
were interested whether this event was also associated with sST2
levels. In total 34 patients (50%) showed signs of bleeding. We
found mild haemorrhages (petechiae, ecchymoses and epistaxis) in
23 cases and severe haemorrhages (gastrointestinal, melaena, gum
bleeding, hemoptysis and heamaturia) in 10 cases. To determine
whether elevated sST2 levels were associated with bleeding, we
performed a binary logistic regression analysis and calculated the
area under the ROC curve (AUC), see Table 3. Elevated sST2
levels were significantly associated with overall haemorrhaging
(mild and severe) (OR 2.0; 95%CI: 1.2–3.6, p=.01; AUC: 0.70,
p=.006) and severe haemorrhaging (OR 5.1; 95%CI: 1.1–23.8,
p=.04; AUC: 0.76, p=.009), but not with mild bleeding alone
(OR 1.3; 95%CI: 0.76–2.2, p=.3; AUC: 0.6, p=.5). As we log-
transformed the original variables, this means that for a ten-fold
increase of plasma sST2 levels, the odds of developing mild or
severe bleeding will be 2.0 times higher, and the odds of
developing severe bleeding 5.1 times higher. None of the cytokines
were significantly associated with (severe) haemorrhaging (see
Table 3).
Soluble ST2 and cytokine levels are associated with
mortality
The association between plasma levels sST2, cytokines and
mortality was calculated using a binary logistic regression (OR,
95% CI) and a ROC approach (AUC). The odds of patients with
leptospirosis dying increased by 2.4 (95%CI: 1.0–5.8, p=.05) with
a ten-fold increase of plasma sST2 levels with an AUC of 0.73
(p=.006). As well the odds of patients with leptospirosis dying
increased by 3.2 (95%CI: 1.4–7.7, p=.008) with an AUC of 0.74
(p=.003), with a ten-fold increase of plasma IL-6 levels. With a
ten-fold increase of plasma IL-8 there was an odds of 6.9 (95%CI:
1.8–27, p=.005) and an AUC of 0.75 (p=.003). The anti-
inflammatory cytokine IL-10 failed to reach significance (OR 1.3;
95%CI: 0.5–3.9, p=.58; AUC: 0.58, p=.40), see Table 3.
Soluble ST2 is not released in whole blood after
stimulation with viable Leptospira
To evaluate whether blood cells are an important source of
sST2 during infection, we undertook an in vitro experiment. We
used a fresh viable pathogenic isolate of Leptospira interrogans serovar
Bataviae strain M. When either human whole blood or isolated
PBMCs were stimulated with different concentrations bacteria, we
could not detect sST2 production after 6 hours incubation
(Figure 2). The same held true for the negative controls. In
contrast, high levels TNF-a were measured as dose dependent
upon stimulation with viable Leptospira.
Discussion
This study reports elevated sST2 levels in patients with severe
leptospirosis. Soluble ST2 levels correlated with other indicators of
inflammation. A unique, significant association between sST2 and
bleeding was observed. As well soluble ST2, IL-6 and IL-8 levels
were all associated with poor outcome in leptospirosis patients.
Previous work has reported elevated sST2 plasma levels in
fifteen septic patients, but in this study no association with
mortality was found [22]. Becerra et al. reported elevated sST2
levels in patients suffering from dengue fever, but in the
convalescent samples sST2 levels were normalized [33]. Since all
patients in this study survived and had only mild disease, no
associations with regard to disease severity and outcome could be
found. The data presented here extends these earlier studies, with
Soluble ST2 in Severe Leptospirosis
www.plosntds.org 3 June 2009 | Volume 3 | Issue 6 | e453Figure 1. Soluble ST2 and cytokine dynamics in patients with severe leptospirosis. The bar graphs show mean soluble ST2 and cytokine
plasma levels for survivors (white) and non-survivors (black). The error bars indicate the standard error of the mean (SEM). The horizontal dotted line
represents the detection limit of the assays. Asterisks in the figure indicate the strength of the statistical difference from healthy controls (* p,0.05, **
p,0.001, *** p,0.0001; Mann-Whitney U test).
doi:10.1371/journal.pntd.0000453.g001
Table 1. Soluble ST2 and cytokines on admission in patient with severe leptospirosis.
Marker (pg/ml) All (n=68) Survivors (n=52) Non-survivors (n=16) Controls p-value
ABC D B C
sST2 1480 (502–4378) 1203 (285–2773) 3596 (1452–8590) ,15 0.006
IL-6 45 (17–135) 27 (16–74) 133 (52–430) ,5 0.003
IL-8 40 (16–98) 32 (51–182) 81 (51–182) ,5 0.003
IL-10 7 (4–18) 6 (4–17) 8 (4–37) ,2.5 0.64
Abbreviations: IQR, interquartile range. Values represent medians with the corresponding IQR range. Statistical difference between survivors and non-survivors was
calculated using the Mann-Whitney U test. A p-value ,0.05 was considered significant.
doi:10.1371/journal.pntd.0000453.t001
Soluble ST2 in Severe Leptospirosis
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homogeneous group of patients.
Leptospirosis patients yielded elevated levels of IL-6 and IL-8
associated with mortality in the present study which were stronger
than sST2. From the literature, several studies have found similar
results presenting data on the association between cytokine levels
and poor outcome in septic patients [34,35]. However, in these
studies the range of cytokine levels from survivors and non-
survivors often overlapped, which means that although the
cytokines are associated with poor outcomes, they are of little or
no prognostic value [36]. In a study by Chierakul et al. elevated
TNF-a and IL-12p40 levels were reported in 28 patients with mild
leptospirosis [4]. The biologically active IL-12p70 heterodimer
was detected in only 4 patients. An other study reported increased
TNF-a levels in four out of eighteen leptospirosis patients [6] . In
this small study, TNF-a was found to be associated with disease
severity and poor outcome. In contrast, in the current work TNF-
a, IL-1b and IL-12p70 concentrations were either very low or
undetectable and did not differ from the controls. The fact that we
could not confirm the association between poor outcome and
TNF-a can be explained by the fact that our patients presented in
late stage disease and TNF-a is considered to be an early response
cytokine.
It is interesting to speculate why (severe) bleeding was found to
be associated with sST2 plasma levels. Weinberg et al. identified
sST2 release in response to myocardial infarction and suggested
that sST2 participates in the cardiovascular response to injury of
the cardiomyocytes [37]. Disruption of the endothelial cell barrier,
a possible explanation for the haemorrhages found in severe
leptospirosis, exposes underlying fibroblasts. In this light, sST2
could be an indicative marker for tissue injury given the fact that
serum stimulation of resting fibroblasts results in sST2 release [9].
Our in vitro experiments with pathogenic Leptospira showed that, at
least in the early phase, blood is not the source of sST2
production. These findings were in line with previous findings of
our group in which we found that membrane bound ST2 is
upregulated on monocytes when whole blood is incubated with
LPS, while sST2 remains undetectable in blood plasma after
24 hour whole blood LPS stimulation [38].
In conclusion, in patients with severe leptospirosis we
demonstrated elevated plasma sST2 levels that normalized during
follow-up and were associated with mortality. Interestingly sST2
Table 2. Correlation between soluble ST2 (sST2), clinical
markers and cytokines on day of admission.
Variable Serum sST2
rho p-value
Pulse 0.20 0.1
RR 20.25 0.04
Leucocytes 20.05 0.7
Platelets 20.25 0.04
Creatinin 0.33 0.007
AST 0.46 0.001
ALT 20.016 0.9
CRP 0.50 ,0.0001
Haemorrhaging 0.34 0.005
Mild 0.10 0.4
Severe 0.32 0.008
TNF-a 0.17 0.2
IL-1b 0.14 0.3
IL-12p70 0.04 0.8
IL-6 0.45 0.001
IL-8 0.72 ,0.0001
IL-10 0.56 ,0.0001
Abbreviations: RR, respiratory rate; CRP, C-reactive protein. The correlation
coefficient (rho) is calculated by the non-parametric Spearman’s rank
correlation test. A p-value,0.05 was considered significant.
doi:10.1371/journal.pntd.0000453.t002
Table 3. Association between soluble ST2 (sST2) bleeding
and mortality.
Variable OR (95%CI) p-value AUC p-value
Bleeding
10-log sST2 2.0 (1.2–3.6) 0.01 0.70 0.006
10-log IL-6 1.8 (0.9–3.7) 0.1 0.61 0.1
10-log IL-8 2.6 (1.0–7.4) 0.06 0.62 0.08
10-log IL-10 1.3 (0.5–3.3) 0.6 0.55 0.5
Severe bleeding
10-log sST2 5.1 (1.1–24) 0.04 0.76 0.009
10-log IL-6 2.0 (0.83–4.9) 0.1 0.66 0.1
10-log IL-8 2.4 (0.77–7.7) 0.1 0.65 0.1
10-log IL-10 2.0 (0.6–6.6) 0.3 0.61 0.3
Mortality
10-log sST2 2.4 (1.0–5.8) 0.05 0.73 0.006
10-log IL-6 3.2 (1.4–7.7) 0.008 0.74 0.003
10-log IL-8 6.9 (1.8–27) 0.005 0.75 0.003
10-log IL-10 1.3 (0.5–3.9) 0.58 0.58 0.4
Abbreviations: OR, odds ratio; CI, confidence interval, AUC, area under the ROC
curve (receiver operating characteristic). Associations are presented as OR with
95% confidence interval and AUC values. A p-value,0.05 was considered
significant.
doi:10.1371/journal.pntd.0000453.t003
Figure 2. In vitro stimulation of whole blood or peripheral
blood mononuclear cells (PBMC) with pathogenic Leptospira.
This bar graph shows mean TNF-a (white) and sST2 (black) levels with
standard error of the mean (SEM) for each group. Either human whole
blood or peripheral blood mononuclear cells (PBMC) were incubated
with various concentrations pathogenic Leptospira. Controls were not
incubated with Leptospira. Soluble ST2 (sST2) and TNF-a levels were
measured in supernatant after 6 hours incubation.
doi:10.1371/journal.pntd.0000453.g002
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More research is warranted to elucidate the function of sST2 in
the innate immune response to Leptospira and to evaluate its value
as a marker for tissue damage in severely ill patients.
Supporting Information
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Found at: doi:10.1371/journal.pntd.0000453.s001 (0.07 MB
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